Gemcitabine and cisplatin are standard drugs used to treat urothelial cancers (those of the bladder, ureters, urethra, and kidney). Not all patients can tolerate cisplatin, however, and they may receive gemcitabine and carboplatin.
The purpose of this study is to assess the safety and effectiveness of gemcitabine and pazopanib in patients with advanced urothelial cancers who have not yet received chemotherapy (“chemotherapy naive”) and are not candidates for cisplatin-based therapy. Pazopanib, which is approved for the treatment of renal cell carcinoma (a form of kidney cancer) interferes with cancer cell growth and reduces the growth of new blood vessels tumors need to grow and spread. Pazopanib is taken orally (by mouth), while gemcitabine is given intravenously (by vein).